| Name | Title | Contact Details |
|---|
Owensboro Medical Health System provides healthcare services to a ten-county area in Southern Indiana and Western Kentucky with a mission of healing the sick and improving the health of the community.
Health Systems International is focused on healthcare affordability for our clients. Our goal is to ensure each interaction is paid at the most affordable amount for all involved. We do this through a set of Payment Integrity Solutions built on our data analytics, cloud-based, multi sided business platform and expertise in Provider and Network Data Management. Our solution set is designed to improve efficiencies, reduce cost, and provide insight though a unique set of prevention, prepayment and post payment solutions. Our company has a rich history in providing cost savings to multiple markets across the healthcare eco-system. Regardless of your specific market segment, be it a Payor, Health plan, TPA, P&C Carrier, Workers’ Compensation Administrator, PBM, HIE or ACO, you want to ensure the reimbursements paid by you and your members are accurate, appropriate, and at the most affordable rate. That is our focus! We bring decades of expertise, a commitment to information and analytics, and most importantly a culture that is dedicated and aligned to creating value for our customers and partners alike.
Prexus Health is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Dedicated Phase 1 is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.